Lv7
5120 积分 2021-11-18 加入
Intracranial delivery of B7-H3-targeting CAR-T cells for recurrent glioblastoma: a phase 1 trial
28天前
已完结
Ifebemtinib plus garsorasib in previously treated metastatic colorectal cancer with KRASG12C mutation: a multicentre, randomised, phase 1b/2 trial
1个月前
已完结
Oral KRAS G12D inhibitor GFH375 for previously treated advanced solid tumors with KRASG12D mutations: a phase 1 trial
1个月前
已完结
Self‐Adapting Priors for Dynamic Borrowing in Three‐Arm Non‐Inferiority Trials With Pre‐Specified Margin
1个月前
已完结
Ivonescimab plus chemotherapy versus placebo plus chemotherapy in patients with advanced EGFR-mutated non-small-cell lung cancer after disease progression on EGFR tyrosine kinase inhibitor therapy (HARMONi): a multicentre, randomised, double-blind, phase 3 trial
1个月前
已完结
Artificial intelligence in drug discovery — what it is, where we stand and the path forward
2个月前
已完结
T cell engagers in autoimmune diseases
2个月前
已完结
PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer
2个月前
已完结
Evolution of KRAS molecular glues: from allele-selective to Pan-RAS and protein–protein interaction modulators
3个月前
已完结
GPC3-specific dnTGFβRII-armoured CAR T cells for hepatocellular carcinoma
3个月前
已完结
Abstract CT092: A Phase 1a/1b, first-in-human study of an ADC targeting ADAM9 (DB-1317) in participants with selected advanced or metastatic solid tumors
皖公网安备34019202002308
